Surabhi Khanna, MD
Rheumatology · San Diego, CANPI 1124220157
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 79.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $7,956 and has fallen 81.5% since, to $1,475 in 2025.
Across 116 payments — averaging $109.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- AbbVie$554
- Amgen$496
- UCB, Inc.$281
- Aurinia Pharma U.S., Inc.$235
- GSK$234
- plus $759 from 11 others
Across 22 payments — averaging $2667.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$30K
- Sanofi US Services Inc.$21K
- Boehringer Ingelheim International GmbH$7K
- Kadmon Corporation LLC$214
What the payments were for
- Consulting fees$3,65029%
- Speaking & faculty fees$6,30250%
- Food & beverage$2,70321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $10,095 |
| AbbVie | 15 | $554 |
| Amgen | 32 | $496 |
| UCB, Inc. | 17 | $281 |
| Aurinia Pharma U.S., Inc. | 7 | $235 |
| GSK | 11 | $234 |
| Mallinckrodt Hospital Products Inc. | 7 | $215 |
| Novartis | 6 | $150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Lilly USA, LLC | 4 | $78 |
| AstraZeneca | 2 | $46 |
| Pfizer | 2 | $45 |
| Bioventus LLC | 1 | $31 |
| Almatica Pharma LLC | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,655 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $95,051 |
| OrenciaAbatacept | 13 | $71,923 |
| ProliaDenosumab | 22 | $37,737 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $21,287 |
| Hydroxychloroquine Sulfate | 199 | $12,659 |
| Colchicine | 33 | $4,251 |
| MethotrexateMethotrexate Sodium | 103 | $3,653 |
| Leflunomide | 35 | $3,410 |
| Mycophenolate Mofetil | 36 | $2,801 |
| Celecoxib | 31 | $2,505 |
| Prednisone | 329 | $2,477 |
| Alendronate Sodium | 171 | $1,572 |
| Duloxetine Hcl | 48 | $1,478 |
| Gabapentin | 61 | $1,130 |
| Azathioprine | 30 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Orencia | $122 | $71,92313 claims |
| AmgenProlia, Evenity (2 Syringes) | $496 | $59,02533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.
Other rheumatology in San Diego
- Ara DikranianSan Diego$2.2M
- Arthur MabaquiaoSan Diego$209K
- Kenneth KalunianSan Diego$194K
- Sudhakar TumuluriSan Francisco$2.8M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.